Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan vs Losartan + Hydrochlorothiazide for Proteinuria in Diabetic Nephropathy
NCT06491940Not yet recruiting
- Sponsor
- RESnTEC (Research and Technology) Ltd
- Start
- Aug 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of hydrochlorothiazide in diabetic nephropathy (DN) (2 arms), sponsored by RESnTEC (Research and Technology) Ltd. Primary endpoint: Reduction of proteinuria at 4 months. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
hydrochlorothiazide
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT06491940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06491940.